Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
Status:
Completed
Trial end date:
2019-05-11
Target enrollment:
Participant gender:
Summary
In this open-label, prospective, randomized pilot study, patients who develop atrial
fibrillation after isolated coronary artery bypass grafting surgery will be identified.
Patients with persistent atrial fibrillation (>12 hours) or recurrent sustained atrial
fibrillation (>2 episodes of atrial fibrillation lasting longer than 30 minutes) will be
candidates for inclusion. Upon meeting study inclusion and exclusion criteria, and after
informed consent, patients will be randomized to either the standard of care (warfarin per
protocol) or apixaban arms of the trial. Routine postoperative care after CABG will occur in
both groups. Upon discharge, anticoagulation in both groups will be managed by the
anticoagulation clinic. Patients will be followed for 30 days after surgery.